Why the study?
Treatment strategies must be tailored to distinct subtypes of liposarcoma, prompting a review of biological characteristics, molecular alterations, and surgical and pharmacological treatments.
Individualized precision therapy and a multidisciplinary approach are essential for managing the heterogeneity of liposarcoma.
Tailored surgery and subtype-specific therapies may improve liposarcoma outcomes; reinforces precision oncology trials over uniform regimens.
Liposarcoma (LPS) is a rare soft tissue sarcoma that develops from the differentiation of fat cells, typically occurring in the lower extremities and retroperitoneal space. Depending on its histological morphology and molecular changes, LPS can be divided into various subtypes, each exhibiting distinct biological behaviors. During treatment, especially for LPS arising in the retroperitoneum, the extent and quality of the initial surgery are critically important. Treatment strategies must be tailored to the specific type of LPS. Over the past few decades, the treatment of LPS has undergone numerous advancements, with new therapeutic approaches such as targeted drugs and immunotherapies continually emerging. This paper reviews the biological characteristics, molecular alterations, as well as surgical and pharmacological treatments of various LPS subtypes, with the aim of enhancing clinicians' understanding and emphasizing the importance of individualized precision therapy. With a deeper understanding of the biological characteristics and molecular alterations of LPS, future treatment trends are likely to focus more on developing personalized treatment plans to better address the various types of LPS. • Due to the heterogeneity of liposarcoma, the available treatment options are limited. • Expanding the scope of surgery with the aim of achieving radical cure is gradually becoming a trend in the surgical treatment of liposarcoma. • Combination drug therapy can enhance efficacy, but potential drug toxicity should also be noted. • A multidisciplinary diagnostic and therapeutic approach holds great potential for the treatment of liposarcoma.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: